Vitestro raises $70 million in Series B to develop autonomous blood-drawing robot

Vitestro announced on March 10, 2026, that it raised $70 million in a Series B round. The round was oversubscribed, with new participants including Labcorp Venture Fund, Mayo Clinic and Sutter Health. The funds will go toward developing the next-generation Aletta, securing U.S. Food and Drug Administration De Novo approval and preparing for commercial expansion in Europe.

The funding is directed not simply at business expansion but specifically at developing a next-generation device for integrating Aletta into operations at high-volume blood-drawing sites, such as outpatient facilities, as well as preparing manufacturing capacity, conducting clinical trials and pursuing regulatory approval. Vitestro says Aletta is designed to locate veins, guide a needle and autonomously perform routine diagnostic blood draws, addressing staff shortages and variability in blood-drawing departments.